Related Experiment Video
Updated: Jun 18, 2026
05:57
The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
Published on: May 17, 2024
[Homocysteine: a casual link with heart failure?].
E Vizzardi1, I Bonadei, G Zanini
1Department of Cardiology, University of Brescia, Brescia, Italy. enrico.vizzardi@tin.it
Minerva Medica
|November 14, 2009
Summary
Hyperhomocysteinemia (HHCY) is a significant risk factor for congestive heart failure (CHF), linked to disease severity. Further research is needed to understand the exact mechanisms connecting HHCY and CHF.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
Context:
- Hyperhomocysteinemia (HHCY) is recognized as an independent risk factor for congestive heart failure (CHF).
- Existing literature suggests a correlation between HHCY levels and CHF severity and prognosis.
- Animal models indicate HCY may directly impact myocardial structure and function.
Purpose:
- To review the current understanding of hyperhomocysteinemia's role in congestive heart failure.
- To highlight the association between HHCY and CHF severity.
- To identify gaps in mechanistic understanding regarding HHCY's pathomechanisms in CHF.
Summary:
- Studies and patents link HHCY to CHF, with HHCY potentially causing myocardial fibrosis, systolic dysfunction, and endothelial/mitochondrial issues.
- While some view HHCY as an etiological factor in heart failure, others consider it an epiphenomenon.
- Despite strong correlations, current epidemiological studies lack mechanistic insights into HHCY's role in CHF.
Impact:
- Underscores the clinical relevance of HHCY in CHF patients.
- Emphasizes the need for further research into the precise pathomechanisms of HHCY in heart failure.
- Informs potential therapeutic strategies targeting HHCY in CHF management.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...